

CLAIMS:

- A nutritional supplement comprising an ester formed between a sterol and an omega-3 fatty acid for lowering cholesterol and triglyceride levels in the bloodstream of a 5 subject.
 - 2. The nutritional supplement according to claim 1, wherein the sterol is a phytosterol.
 - 3. The nutritional supplement according to claim 1 or 2, wherein the omega-3 fatty acid has the formula:

10

wherein R^1 is a (C_3-C_{40}) alkenylene group comprising at least one double bond.

- 15 4. The nutritional supplement according to claim 3, wherein \mathbb{R}^1 has from 2 to 5 double bonds.
 - 5. The nutritional supplement according to claim 4, wherein the omega-3 fatty acid is eicosapentaenoic acid $20:5\omega 3$ (EPA).
- 20 6. The nutritional supplement according to claim 4, wherein the omega-3 fatty acid is docosahexaenoic acid $22:6\omega 3$ (DHA).
 - 7. The nutritional supplement according to any one of claims 1 to 6, wherein the sterol is a phytosterol.

WO 01/15552



- 8. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is stigmasterol.
- 9. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is sitosterol.
- 5 10. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is fucosterol.
 - 11. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is fucostanol.
- 12. The nutritional supplement according to any one of 10 claims 1 to 7, wherein the sterol is β -sitostanol.
 - 13. The nutritional supplement according to any one of claims 1 to 12, further comprising an edible additive.
 - 14. A method of lowering cholesterol and triglyceride levels in the bloodstream of a subject, the method including
- 15 the step of administering to a subject an effective amount of a nutritional supplement comprising an ester formed between a sterol and an omega-3 fatty acid.
 - 15. The method according to claim 14, wherein the omega-3 fatty acid is derived from fish oil.
- 20 16. The method according to claim 14 or 15, wherein the omega-3 fatty acid has the formula:

$$CH_3$$
— CH_2 — CH = CH — R^1 — C — OH

25 wherein R^1 is a (C_3-C_{40}) alkenylene group comprising at least one double bond.

WO 01/15552





- 17. The method according to claim 16, wherein R¹ has from 2 to 5 double bonds.
- 18. The method according to claim 17, wherein the omega-3 fatty acid is eicosapentaenoic acid $20:5\omega 3$ (EPA).
- 5 19. The method according to claim 17, wherein the omega-3 fatty acid is docosahexaenoic acid $22:6\omega3$ (DHA).
 - 20. The method according to any one of claims 14 to 19, wherein the sterol is a phytosterol.
- 21. The method according to any one of claims 14 to 20, 10 wherein the sterol is stigmasterol.
 - 22. The method according to any one of claims 14 to 20, wherein the sterol is sitosterol.
 - 23. The method according to any one of claims 14 to 20, wherein the sterol is fucosterol.
- 15 24. The method according to any one of claims 14 to 20, wherein the sterol is fucostanol.
 - 25. The method according to any one of claims 14 to 20, wherein the sterol is β -sitostanol.
- 26. Use of a nutritional supplement comprising an ester 20 formed between a sterol and an omega-3 fatty acid, as defined in any one of claims 1 to 13, for lowering cholesterol and triglyceride levels in the bloodstream of a subject.
- 27. A foodstuff having a nutritional value enhanced by incorporation of the nutritional supplement according to any 25 one of claims 1 to 13.

WO 01/15552





- 28. Use of the nutritional supplement according to any one of claims 1 to 13 in the manufacture of a foodstuff.
- 29. A process for preparing the nutritional supplement as defined in any one of claims 1 to 13, which comprises the step 5 of reacting a sterol with an omega-3 fatty acid, or an ester thereof, in the presence of a base.
 - 30. A process according to claim 29 wherein the base is a metal (C_1-C_{10}) alkoxide.
- 31. A process according to claim 30, wherein the metal (C_1-C_{10}) is sodium methoxide.
 - 32. A process according to claim 29, 30 or 31, which further comprises the step of precipitating unreacted sterol with a suitable non-polar solvent, and filtering off the precipitated unreacted sterol to leave a filtrate.
- 15 33. A process according to claim 32, wherein the non-polar solvent is hexane.
- 34. A process according to claim 32 or 33, which further comprises the step of extracting the filtrate with a suitable immiscible solvent to remove unreacted omega-3 fatty acid, or 20 an ester thereof, from the filtrate.
 - 35. A process according to claim 34, wherein the immiscible solvent is methanol.
- 36. A process according to any one of claims 29 to 35, wherein the ester of the omega-3 fatty acid is a triglyceride 25 ester.
 - 37. A process according to any one of claims 29 to 35, wherein the ester of the omega-3 fatty acid is an ethyl ester.